WGS · Nasdaq · Healthcare
GeneDx Holdings Corp. (WGS) — Rank #46 by gross profitability (GP/assets 0.62) · ROE -8.6% · Piotroski F-Score 6 / 9.
As-of 2026-10-30 · CIK 0001818331 · all metrics point-in-time as of the filing date.
About
GeneDx Holdings Corp., a genomics company, provides genetic testing services.
Show moreShow less
The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp.
was founded in 2000 and is headquartered in Stamford, Connecticut.
- Industry
- Diagnostics & Research
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- genedx.com
Company Snapshot
P/S is the primary valuation lens — earnings are reinvested, not available for P/E.
Market Cap
—
P/E (annual)
—
P/S (annual)
—
P/B
—
P/OCF (annual)
—
Shareholder Yield
—
Employees
1,300
Industry
Diagnostics & Research
Exchange
Nasdaq
10/12
Flags passed
WGS passes 10/12 quality flags
2 cautions to review
- CAUTIONDilution above 2%
Annual share count increase exceeds 2%. May be acceptable for high-growth companies funding talent via stock compensation
- CAUTIONDisclosure regression
A previously-disclosed line item is no longer reported — worth checking the filing for why
- PASSGross margin holding
- PASSFCF not negative from investment
- PASSRevenue not declining
- PASSOperating margin holding
- PASSFree cash flow intact
- PASSPasses safety gate
- PASSBalance sheet stable
- PASSNo competitive retreat
- PASSSBC not compressing margin
- PASSNo valuation convergence
A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
1/2 passRevenue growth and the path to profitability (margin trend) are the primary reads at this stage.
Profitability
Does it make money well?
No warning flags · GP/assets 0.62
Gross profitability (GP / assets)
0.62
Primary signal (Novy-Marx).
2nd of 7 SIC 80 peers
Return on equity
-8.6%
Gross margin
69.7%
2nd of 7 SIC 80 peers
Revenue growth (YoY)
40.0%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
22.1%
Revenue CAGR (5Y)
19.0%
Earnings CAGR (3Y)
—
FCF CAGR (3Y)
—
Cash Flow Health
Is the cash real?
No warning flags · FCF 168% above net income
Free cash flow
$14.26M
Operating cash flow minus capex.
Positive free cash flow
FCF vs net income
167.8%
(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.
FCF not below net income
Fails when free cash flow is below net income (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
7.5%
Stock-based comp intensity.
Balance Sheet Strength
Can it survive a storm?
Caution: Dilution above 2% · net cash $35.71M, F-Score 6/9
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
0.97
4th of 6 SIC 80 peers (best = lowest)
Current ratio
3.30×
3rd of 7 SIC 80 peers
Quick ratio
2.90×
Net cash
$35.71M
Cash & equivalents minus total debt.
Piotroski F-Score
6 / 9
Fundamental-strength score (0-9).
Valuation
Is the price reasonable?
No warning flags
Capital allocation quality
Composite score
2.7 / 5
Lifecycle Phase History
Price History
Source filings on SEC EDGAR: 10-K annual reports · 10-Q quarterly reports